Health & Fitness
Health and Fitness
Health and Fitness
Tue, June 22, 2010Mon, June 21, 2010Sun, June 20, 2010Fri, June 18, 2010Thu, June 17, 2010Wed, June 16, 2010Tue, June 15, 2010Mon, June 14, 2010Sat, June 12, 2010Fri, June 11, 2010Thu, June 10, 2010Wed, June 9, 2010Tue, June 8, 2010Mon, June 7, 2010Sun, June 6, 2010Sat, June 5, 2010Fri, June 4, 2010Curis Announces Change to Presentation Time at ThinkEquitya?s Mid Year Check-up on Healthcare Conference
Published in Health and Fitness on Monday, June 14th 2010 at 7:45 GMT by Market Wire
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its presentation time for the upcoming ThinkEquity Mid Year Check-up on Healthcare Conference has been changed to 10:00 a.m. EDT on June 16, 2010, in New York City.
Dan Passeri, Curisa™ President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor. GDC-0449 is currently being developed in three Phase II clinical trials by Curisa™ collaborator Genentech, including in a pivotal Phase II trial in advanced basal cell carcinoma and Phase II trials in metastatic colorectal cancer and advanced ovarian cancer. Mr. Passeri will also discuss CUDC-101, Debio 0932 and Curis' other targeted cancer programs, in addition to other corporate activities.
There will be a corresponding webcast of the presentation, which can be accessed by visiting: [ http://www.wsw.com/webcast/tep18/cris/ ]
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at [ www.curis.com ].
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at [ www.curis.com ].
